Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Completed
Pfizer
Phase 3
2005-09-01
Efficacy, tolerability and safety of olmesartan alone or in combination with
hydrochlorothiazide in the treatment of mild to moderate essential hypertension
VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
Completed
Novartis
Phase 3
2004-12-01
To evaluate the efficacy of valsartan 160 mg/HCTZ 25 mg in patients not adequately responding
to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan
medoxomil 20 mg plus HCTZ 12.5 mg by testing the hypothesis that valsartan 160 mg/HCTZ 25 mg
significantly reduces the trough mean sitting diastolic blood pressure (MSDBP) after a 4-week
treatment in the nonresponder population.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
